Press Release Mar 14 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Colestipol Hydrochloride Tablets. This approval allows Zydus to market the drug, which is used to help reduce elevated cholesterol levels in patients. The company notes that this is only the second generic application approved by the USFDA for this product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 09 2022
- Press Release Mar 08 2022
- Press Release Mar 07 2022
- Press Release Feb 23 2022
- Press Release Feb 14 2022
Later from Zydus Lifesciences
- Press Release Mar 21 2022
- Press Release Apr 01 2022
- Press Release Apr 13 2022
- Press Release Apr 18 2022
- Press Release Apr 25 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences